The impact of the Oncotype Dx (ODX) breast cancer assay on adjuvant chemotherapy (ACT)
treatment decisions has been evaluated in many previous studies. However, it can be …

Prostate cancer (PCa) is the most prevalent cancer with a high mortality rate. The early and
accurate detection of PCa can significantly reduce mortality and saves lives. Hence, the …

Abstract Background The Oncotype DX breast recurrence score has been introduced more
than a decade ago to aid physicians in determining the need for systemic adjuvant …

Abstract The 21-gene Recurrence Score assay is validated to predict recurrence risk and
chemotherapy benefit in hormone-receptor-positive (HR+) invasive breast cancer. To …

What does it mean to personalise cancer medicine? Personalised cancer medicine explores
this question by foregrounding the experiences of patients, carers and practitioners in the …

Abstract Purpose The Oncotype DX® Breast Recurrence Score™(RS) assay is validated to
predict breast cancer (BC) recurrence and adjuvant chemotherapy benefit in select patients …

Background MRI has been used increasingly in the diagnosis and management of women
with invasive breast cancer. However, its usefulness in the preoperative assessment of …

Objective We hypothesized that the Oncotype Dx® 21‐gene Recurrence Score (RS) could
guide neoadjuvant systemic therapy (NST) to facilitate breast conserving surgery (BCS) for …

Abstract The Recurrence Score® is increasingly used in node-positive ER+ HER2-negative
breast cancer. This retrospective analysis of a prospectively designed registry evaluated …

Precision Medicine involves the delivery of a targeted, personalized treatment for a given
patient. By harnessing the power of electronic health records (EHRs), we are increasingly …